List of Excipients in Branded Drug PENTETATE ZINC TRISODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
hameln pharma gmbh	PENTETATE ZINC TRISODIUM	pentetate zinc trisodium	70651-002	SODIUM HYDROXIDE
hameln pharma gmbh	PENTETATE ZINC TRISODIUM	pentetate zinc trisodium	70651-002	WATER
hameln pharma gmbh	PENTETATE ZINC TRISODIUM	pentetate zinc trisodium	70651-002	ZINC OXIDE

Pentetate Zinc Trisodium Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 24, 2026

Pentetate zinc trisodium, also known as zinc-DTPA or Zn-DTPA, is an injectable decorporation agent used to enhance urinary elimination of plutonium, americium, or curium after internal radioactive contamination. Its commercial value is concentrated in government stockpiles, emergency preparedness contracts, hospital readiness, and specialized radiological-response channels rather than routine outpatient prescribing. The formulation opportunity is narrow: a low-excipient, metal-controlled sterile injection with strong container-closure and long-term stability performance.

What is pentetate zinc trisodium used for?

Pentetate zinc trisodium is a chelating agent that binds transuranic radionuclides and promotes their excretion. It is administered intravenously after internal contamination with plutonium, americium, or curium. Calcium-DTPA is generally preferred for the initial treatment when available; zinc-DTPA is used after the first 24 hours and for longer-term treatment because it has a lower tendency to remove essential metals from the body [1, 2].

Attribute	Pentetate zinc trisodium
Generic name	Pentetate zinc trisodium
Common abbreviation	Zn-DTPA
Therapeutic category	Radiological decorporation agent
Route	Intravenous administration
Typical adult dose	1 gram, generally administered as a single dose
Primary targets	Plutonium, americium, curium
Regulatory status	FDA-approved prescription medical countermeasure
Commercial market	Government stockpiles, federal procurement, emergency hospitals, specialized distributors
Biosimilar relevance	None; this is a small-molecule drug
Formulation type	Sterile aqueous injectable solution

The product does not treat external radiation exposure or ordinary radiation sickness. It is intended for internal contamination involving specific transuranic elements.

What excipients are used in pentetate zinc trisodium injection?

The commercial formulation is deliberately simple. The U.S. labeling identifies water for injection as the principal vehicle and hydrochloric acid and/or sodium hydroxide for pH adjustment. The absence of preservatives, buffers, surfactants, or antimicrobial excipients reduces compatibility risks for a highly metal-binding active ingredient [1].

Formulation component	Function	Strategic significance
Pentetate zinc trisodium	Active pharmaceutical ingredient	Requires control of chelation capacity, zinc content, purity, and degradation products
Water for injection	Vehicle	Must meet parenteral water quality requirements
Hydrochloric acid	pH adjustment	Adds chloride and acidity; must not create precipitation or container interaction
Sodium hydroxide	pH adjustment	Controls final pH and neutralization
Preservatives	Not normally included	Avoids toxicity, compatibility, and emergency-use concerns
Surfactants	Not normally included	Avoids adsorption and extractables risks
Chelating stabilizers	Not normally included	Could compete with DTPA or alter radionuclide binding behavior
Antioxidants	Not normally included	Limited value unless a defined oxidation pathway is demonstrated

A low-excipient design is commercially preferable because Zn-DTPA is itself a powerful chelator. Excipients containing metal ions, polyvalent cations, or reactive impurities could affect the active ingredient’s coordination chemistry or create analytical interference.

How should the excipient strategy be designed for Zn-DTPA?

Control metal contamination

The main formulation risk is uncontrolled interaction with trace metals. Manufacturing systems, water systems, stainless-steel contact surfaces, filters, elastomers, and glass components can contribute iron, copper, nickel, chromium, or other elemental impurities. These metals can consume chelation capacity, change solution color, alter impurity profiles, or complicate release testing.

A commercial development program should establish:

• Elemental impurity limits for the drug product and process streams.
• Controls for iron, copper, zinc, calcium, magnesium, nickel, chromium, and lead.
• Low-metal raw-material specifications.
• Validated cleaning procedures for manufacturing equipment.
• A metal balance from active pharmaceutical ingredient through final container.
• Stability monitoring for changes in assay, free ligand, zinc content, and visible or subvisible particles.

ICH Q3D provides the general framework for elemental impurity risk assessment, but Zn-DTPA requires a product-specific approach because metal binding is central to its pharmacology rather than an incidental impurity issue [3].

Avoid unnecessary buffers

A conventional phosphate, citrate, acetate, or histidine buffer may introduce additional coordination chemistry. Such systems should not be added unless they solve a demonstrated pH or stability problem. Sodium chloride also should not be used automatically to adjust tonicity because it increases ionic strength and may affect administration volume or compatibility.

The preferred starting formulation is:

1. Zn-DTPA at the labeled concentration.
2. Water for injection.
3. pH adjustment with hydrochloric acid and sodium hydroxide.
4. No preservative.
5. No surfactant.
6. No added chelator.

This approach reduces the number of formulation variables and supports a clean regulatory comparability package.

Optimize pH and osmolality as product attributes

The final pH should be controlled within the approved labeling range and validated across the product shelf life. A formulation that drifts toward acid or alkaline conditions could affect container closure integrity, precipitation behavior, patient tolerability, and assay results.

The development target should balance:

• Chemical stability.
• Zinc retention.
• Absence of visible particles.
• Low injection-site irritation risk.
• Compatibility with intravenous administration.
• Acceptable osmolality without unnecessary salt loading.

Any pH adjustment system should be justified by stability data. The commercial advantage of Zn-DTPA does not depend on formulation complexity. It depends on reproducible quality and reliable availability during a low-frequency, high-consequence event.

What formulation patents protect pentetate zinc trisodium?

The core drug substance is an established chelating compound and is unlikely to support meaningful new-molecule exclusivity in the current market. The principal commercial protection opportunities are therefore formulation, manufacturing, packaging, and delivery claims rather than composition-of-matter claims.

Potentially protectable areas include:

• A low-metal sterile aqueous formulation.
• A defined pH range that improves long-term stability.
• A low-extractables container-closure system.
• A ready-to-administer presentation.
• A concentrated or reduced-volume formulation.
• A process that limits metal contamination.
• A specific sterilization or aseptic-processing sequence.
• A lyophilized formulation for reconstitution, if technically justified.
• A combination emergency kit containing Zn-DTPA and administration components.
• A differentiated method of use involving delayed or repeated treatment.

A patent on a new excipient combination would face a high commercial hurdle if the excipient does not produce a measurable improvement in stability, sterility assurance, administration, storage, or clinical use. A simple substitution of one pH adjuster or container material is unlikely to support durable market exclusivity without comparative data.

Does pentetate zinc trisodium have active composition patents?

The product’s original composition-of-matter protection would be expected to have expired because DTPA compounds have been known and used for decades. The current commercial assessment should focus on later-filed formulation and process patents, not the original molecule.

No biosimilar patent pathway applies. Zn-DTPA is a small molecule and would be addressed through an abbreviated or alternative small-molecule application pathway, depending on the reference product, formulation, labeling, and FDA requirements.

What is the Orange Book status of pentetate zinc trisodium?

Orange Book treatment should be verified against the current FDA listing and the specific reference product. Emergency medical countermeasures can have limited commercial listings and may not present the same patent-density profile as major chronic-care drugs. The likely protection model for Zn-DTPA is regulatory approval, government procurement, manufacturing know-how, and supply reliability rather than an extensive Orange Book patent estate [4].

A prospective entrant should review:

• FDA-approved product and labeling records.
• Current Orange Book listing status.
• Reference-listed-drug status.
• Any listed patents or exclusivity codes.
• Drug substance and drug product requirements.
• Whether the proposed product qualifies for an ANDA or requires a different application strategy.

When does pentetate zinc trisodium lose exclusivity?

The original molecule is not the principal source of current exclusivity. Any remaining exclusivity would more likely arise from product-specific approval history, orphan-drug provisions, pediatric provisions, or later formulation patents. The FDA labeling record should be used to confirm the applicable approval and exclusivity history [1, 4].

For commercial planning, the relevant expiration question is not simply the end of a historic chemical patent. It is whether an entrant can obtain approval and establish a reliable supply channel before the incumbent’s government contracts, emergency procurement relationships, or institutional accounts renew.

Are there Paragraph IV challenges or patent litigation involving Zn-DTPA?

Pentetate zinc trisodium has not developed the visible Paragraph IV litigation profile associated with blockbuster drugs. Its market is small, specialized, and often procurement-driven. The commercial risk is more likely to involve:

• Regulatory approval timing.
• Qualification for federal stockpile procurement.
• Manufacturing capacity.
• Sterile injectable compliance.
• Raw-material availability.
• Contract access.
• Product allocation during an emergency.

A Paragraph IV strategy would be commercially relevant only if an active listed patent materially blocked approval. A formulation or process patent could create a narrower challenge than a composition patent, but the economic incentive would depend on confirmed purchase volumes and procurement access.

Publicly reported settlement activity is not a defining feature of this market. The absence of high-profile litigation does not eliminate freedom-to-operate risk for a proposed formulation, manufacturing process, or device.

What manufacturing and intellectual-property barriers affect Zn-DTPA?

The greatest barriers are operational rather than molecular.

Sterile injectable manufacturing

A prospective manufacturer needs validated aseptic processing, container-closure integrity testing, particulate control, endotoxin controls, and a stable supply of qualified vials or ampoules. Low-volume products can carry high unit costs because sterile manufacturing lines must be scheduled and maintained even when commercial demand is intermittent.

Analytical control

The analytical package should distinguish among:

• Total Zn-DTPA.
• Free DTPA or related ligand impurities.
• Zinc content.
• Trace metals.
• Degradation products.
• Particulate matter.
• pH and osmolality.
• Sterility and bacterial endotoxins.

Inductively coupled plasma methods may be important for elemental profiling. The assay should demonstrate that the active chelation capacity is preserved, not merely that total organic content remains within specification.

Container closure

Glass and elastomer compatibility require specific extractables and leachables work. The container must not release metals or organic compounds that alter the product during extended storage. A ready-to-use vial in a robust secondary package may be more valuable than a novel excipient because it improves deployment reliability.

What commercial opportunities exist for pentetate zinc trisodium?

Federal and state stockpiles

The strongest opportunity is government procurement for radiological and nuclear emergency response. Demand is episodic, but contracts can provide predictable revenue and justify dedicated inventory. The Strategic National Stockpile and related federal preparedness programs are important potential channels [5].

Dual-product emergency portfolios

A supplier that offers both calcium-DTPA and zinc-DTPA can provide a more complete decorporation portfolio. This may improve procurement competitiveness because treatment protocols distinguish between initial calcium-DTPA use and subsequent zinc-DTPA use.

Ready-to-administer packaging

A single-dose vial with clear labeling, tamper evidence, administration instructions, and a long shelf life can improve deployment. Packaging improvements may be commercially stronger than adding excipients.

International radiological preparedness

Countries with nuclear power programs, research reactors, military nuclear capabilities, or large radiological medicine networks may purchase emergency inventories. Geographic expansion requires local regulatory approval, pharmacopoeial compliance, language-specific labeling, and national stockpile qualification.

Contract manufacturing and reserve capacity

A manufacturer can generate value through:

• Government reserve manufacturing.
• Private-label supply.
• Regional licensing.
• Secondary-source qualification.
• Fill-finish services.
• Emergency surge capacity.
• Stability-storage programs.

Reformulation opportunities

Potential differentiated products include:

Opportunity	Commercial value	Development risk
Low-metal ready-to-use vial	High	Low to moderate
Improved container closure	Moderate to high	Moderate
Reduced-volume injection	Moderate	Moderate to high
Autoinjector or wearable delivery	Uncertain	High
Lyophilized product	Uncertain	High
Combination emergency kit	Moderate	Regulatory and logistics complexity
Premixed IV bag	Moderate	Stability and administration concerns

An autoinjector is less straightforward because Zn-DTPA is generally administered intravenously and emergency treatment may require clinical assessment. A device strategy should not assume that convenience alone supports a viable product.

How does Zn-DTPA compare with calcium-DTPA?

Issue	Zn-DTPA	Calcium-DTPA
Primary use	Treatment after the initial period and longer-term decorporation	Preferred initial treatment when available
Metal component	Zinc	Calcium
Essential-metal depletion risk	Lower than calcium-DTPA	Higher with repeated or prolonged use
Formulation strategy	Low-metal aqueous injection	Similar low-excipient strategy
Commercial positioning	Follow-on treatment and stockpile continuity	Initial emergency treatment
Portfolio value	Strong as part of a two-product offering	Strong as the first-line companion product

The two products should be evaluated as a portfolio rather than as direct substitutes. A supplier with only Zn-DTPA may have a narrower procurement proposition than a supplier able to offer both products.

What generic entry risks exist for pentetate zinc trisodium?

Generic entry risk is moderate from a technical perspective and potentially high from a commercial perspective.

Technically, the drug is an aqueous injectable with a limited excipient profile. This can simplify formulation development. Commercially, low volumes, government qualification, sterile manufacturing requirements, and uncertain emergency demand can deter entrants.

The main entry scenarios are:

1. A direct injectable competitor using the same active ingredient and a comparable composition.
2. A 505(b)(2)-type product with a modified concentration, container, or administration presentation.
3. A contract-manufactured product sponsored by a government-focused pharmaceutical company.
4. A dual calcium-DTPA/zinc-DTPA portfolio entrant.
5. An international supplier seeking U.S. approval and stockpile contracts.

The most credible competitive advantage is dependable supply, validated shelf life, and government contracting capability. A novel excipient alone is unlikely to change market structure.

How strong is the patent estate for pentetate zinc trisodium?

The patent estate is likely weak at the active-ingredient level and potentially meaningful at the product and process level. The strongest defensible assets would be:

• Demonstrated stability improvements.
• Metal-contamination controls.
• Container-closure systems.
• Proprietary sterile manufacturing methods.
• Long-term data supporting extended storage.
• Procurement-specific supply arrangements.
• Regulatory dossiers and manufacturing know-how.

Patent strength should be assessed claim by claim. Broad claims covering Zn-DTPA in water for injection would face validity and prior-art pressure. Narrow claims tied to a defined pH, metal threshold, packaging system, or stability result may be more defensible but will provide limited freedom to operate if competitors can design around them.

Key Takeaways

• Pentetate zinc trisodium is a specialized radiological decorporation injection, not a conventional high-volume pharmaceutical.
• The preferred excipient strategy is minimal: water for injection with hydrochloric acid and/or sodium hydroxide for pH adjustment.
• Trace-metal control is the central formulation and manufacturing issue.
• The strongest commercial opportunities involve government stockpiles, emergency preparedness, dual-product Ca-DTPA/Zn-DTPA portfolios, and reliable sterile supply.
• The molecule is not a biosimilar product and is unlikely to have meaningful new-molecule exclusivity.
• Formulation, process, packaging, and deployment patents are more relevant than composition-of-matter patents.
• Generic entry is technically feasible but commercially constrained by low demand, sterile manufacturing, procurement qualification, and inventory requirements.
• A ready-to-use, long-shelf-life presentation may create more value than a complex excipient system.

FAQs

Can pentetate zinc trisodium be formulated with preservatives?

A preservative-free formulation is generally preferable for an injectable emergency product. A preservative would require justification based on repeated-use packaging, microbial-risk reduction, compatibility, toxicity, and regulatory necessity.

Is pentetate zinc trisodium suitable for an oral dosage form?

The approved product is an injectable drug. An oral formulation would require a new development program addressing absorption, gastrointestinal stability, systemic exposure, radionuclide binding, and clinical effectiveness.

Could a metal-free manufacturing process support a patent?

Potentially, but the claim would need to define a novel and non-obvious process or product attribute. A generic statement that manufacturing uses low-metal equipment would likely be insufficient without measurable product or stability advantages.

Does pentetate zinc trisodium require a biosimilar application?

No. Zn-DTPA is a small molecule. A follow-on product would use a small-molecule regulatory pathway rather than the FDA biosimilar pathway.

Is a combination calcium-DTPA and zinc-DTPA product commercially attractive?

Yes, particularly for government and institutional procurement. A combined portfolio aligns with treatment sequencing, but the products may still require separate presentations, dosing instructions, stability programs, and regulatory labeling.

References

1. U.S. Food and Drug Administration. (n.d.). Pentetate zinc trisodium injection prescribing information. FDA/DailyMed labeling.

2. Centers for Disease Control and Prevention. (n.d.). Radiation emergencies: Medical countermeasures for internal contamination. U.S. Department of Health and Human Services.

3. International Council for Harmonisation. (2022). ICH Q3D(R2): Guideline for elemental impurities. ICH.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. Administration for Strategic Preparedness and Response. (n.d.). Strategic National Stockpile. U.S. Department of Health and Human Services.